Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension

Eur Respir J. 2001 Apr;17(4):647-52. doi: 10.1183/09031936.01.17406470.

Abstract

There are no reliable predictors of mortality in primary pulmonary hypertension (PPH). This study assessed whether exercise oxygen desaturation and distance achieved during a six-minute walk are associated with mortality in moderately symptomatic patients with PPH. Thirty-four patients with PPH underwent a pretreatment six-minute walk test, and an invasive haemodynamic assessment of pulmonary vasodilator reserve, to select the best treatment option (epoprostenol in 27 and nifedipine in 7). Median follow-up was 26 months (12 months for the nonsurvivors was 26%), and median survival, >46 months by Kaplan-Maier estimate. The mean+/-SD distance walked was 275+/-155 m and reduction in arterial oxygen saturation (Sa,O2) at maximal distance (deltaSa,O2) was 8.4+/-4.5%). A distance < or =300 m increased mortality risk by 2.4, and a deltaSa,O2 of > or = 10% increased mortality risk by 2.9. Only Sa,O2 at peak distance, deltaSa,O2 and pulmonary vascular resistance (PVR) were related to mortality. After adjusting for PVR, there remained a 27% increase in risk of death for each per cent decrease in Sa,O2. The six-minute walk distance and exercise oxygen saturation may be helpful in selecting patients with primary pulmonary hypertension for whom transplant listing is appropriate.

MeSH terms

  • Adult
  • Aged
  • Antihypertensive Agents / therapeutic use
  • Epoprostenol / therapeutic use
  • Exercise Test*
  • Female
  • Follow-Up Studies
  • Humans
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / mortality*
  • Hypertension, Pulmonary / physiopathology*
  • Male
  • Middle Aged
  • Nifedipine / therapeutic use
  • Oxygen / blood*
  • Pulmonary Circulation
  • Survival Rate
  • Vascular Resistance
  • Vasodilator Agents / therapeutic use
  • Walking*

Substances

  • Antihypertensive Agents
  • Vasodilator Agents
  • Epoprostenol
  • Nifedipine
  • Oxygen